Even with this transformation, we have remained steadfast in advancing the critical development steps for our lead asset, SNT-5505, which sits at the heart of our pipeline and embodies the promise of our work. Our phase 2 trial in myelofibrosis has achieved full recruitment, a milestone that strengthens the foundation of our ongoing hematology program. Additionally, we were pleased to report that we successfully attracted non-dilutive funding for two new studies focused on myelodysplastic syndrome (MDS), which are slated to begin next year. This funding is a significant achievement that highlights the externally recognised value and potential of SNT-5505, ensuring that we continue to invest in our science while respecting our shareholders’ interests
Enjoy the Day ,,NZT
SNT Price at posting:
4.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)